Embolx Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 17


  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.63M

  • Investors
  • 14

Embolx General Information


Developer of balloon occlusion microcatheters designed to treat cancerous tumors, benign prostatic hyperplasia and uterine fibroids. The company's microcatheters set a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues, enabling doctors to improve treatment for a variety of conditions and kill the tumor.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Surgical Devices
Corporate Office
  • 530 Lakeside Drive
  • Suite 200
  • Sunnyvale, CA 94085
  • United States
+1 (408) 000-0000

Embolx Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Embolx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 31-Oct-2022 $1.63M 000.00 Completed Generating Revenue
11. Later Stage VC 01-Jan-2022 00000 000.00 Completed Generating Revenue
10. Later Stage VC (Series C) 01-Jul-2021 00.00 000.00 000.00 Completed Generating Revenue
9. Debt - PPP 13-Apr-2020 00.00 Completed Generating Revenue
8. Accelerator/Incubator 01-Jun-2019 00.00 Completed Generating Revenue
7. Grant 06-Apr-2018 000 00.00 Completed Generating Revenue
6. Early Stage VC (Series B) 01-Nov-2017 00.00 00.00 000.00 Completed Generating Revenue
5. Early Stage VC (Series A2) 15-Jun-2016 00.000 00.000 000.00 Completed Generating Revenue
4. Grant 25-Sep-2015 $1.11M $1.75M Completed Generating Revenue
3. Grant 01-Jan-2015 $447K $1.75M Completed Generating Revenue
To view Embolx’s complete valuation and funding history, request access »

Embolx Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 000,000 00 000.00 000.00 00 000.00 00.000
Series B 000,000 00 000.00 000.00 00 000.00 00.000
Series A2 000,000 00 000.00 000.00 00 000.00 0.000
Series A1 404,836 8% $3.74 $3.74 1x $3.74 14.41%
Series A 151,874 8% $3.29 $3.29 1x $3.29 5.4%
To view Embolx’s complete cap table history, request access »

Embolx Comparisons

HQ Location
Total Raised
Post Valuation
Developer of balloon occlusion microcatheters designed to treat cancerous tumors, benign prostatic hyperplasia and uteri
Surgical Devices
Sunnyvale, CA
17 As of 2024
0000000000 0 000.00


esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
0000 00000000
Westminster, CO
000 As of 0000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Embolx Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TriSalus Life Sciences Formerly VC-backed Westminster, CO 000 00000 000000000 00000
You’re viewing 1 of 1 competitors. Get the full list »

Embolx Executive Team (7)

Name Title Board Seat Contact Info
Michael Allen Founder, Chief Executive Officer, President & Board Member
Michael Lin Director of Finance
Ben Felipe Director of Sales
Frank Grillo Secretary & Board Member
You’re viewing 4 of 7 executive team members. Get the full list »

Embolx Board Members (6)

Name Representing Role Since
Frank Grillo Self Secretary & Board Member 000 0000
Michael Allen Embolx Founder, Chief Executive Officer, President & Board Member 000 0000
Norm Gitis Ph.D Band of Angels Chairman 000 0000
Paul Rogan Self Board Member 000 0000
Robert de Neve Embolx Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Embolx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Embolx Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Acorn Campus Taiwan Venture Capital Minority 000 0000 000000 0
Keiretsu Forum Angel Group Minority 000 0000 000000 0
Xandex Ventures Corporate Venture Capital Minority 000 0000 000000 0
MedTech Innovator Accelerator/Incubator Minority 000 0000 000000 0
VI Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Embolx FAQs

  • When was Embolx founded?

    Embolx was founded in 2013.

  • Who is the founder of Embolx?

    Michael Allen is the founder of Embolx.

  • Who is the CEO of Embolx?

    Michael Allen is the CEO of Embolx.

  • Where is Embolx headquartered?

    Embolx is headquartered in Sunnyvale, CA.

  • What is the size of Embolx?

    Embolx has 17 total employees.

  • What industry is Embolx in?

    Embolx’s primary industry is Surgical Devices.

  • Is Embolx a private or public company?

    Embolx is a Private company.

  • What is Embolx’s current revenue?

    The current revenue for Embolx is 00000.

  • How much funding has Embolx raised over time?

    Embolx has raised $16.5M.

  • Who are Embolx’s investors?

    Acorn Campus Taiwan, Keiretsu Forum, Xandex Ventures, MedTech Innovator, and VI Ventures are 5 of 14 investors who have invested in Embolx.

  • Who are Embolx’s competitors?

    TriSalus Life Sciences is a competitor of Embolx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »